Both CD8+ and CD4+T cells can mount responses against many human cancer types, especially those with higher mutational burden (3, 27) and several studies in different tumour types have shown a correlation between tumor-infiltrating effector CD8+ T cells and favorable clinical outcomes (1) (28). This evidence concerns the gene CD8A and neoplasm.